Treatment of Prostate Cancer in the 21st Century-Future Directions

European Urology, Supplements

Volumn 5, Issue 15, 2006, Pages 824-829

  Eisenberger, Mario ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Chemotherapy; Docetaxel; Hormone refractory prostate cancer; HRPC; Multidisciplinary; TAX 327

Indexed keywords

ANTIANDROGEN; ATRASENTAN; BEVACIZUMAB; CALCITRIOL; CANCER VACCINE; DENOSUMAB; DOCETAXEL; ESTRAMUSTINE; IMATINIB; INFLIXIMAB; MITOXANTRONE; MLN 2704; MONOCLONAL ANTIBODY; OBLIMERSEN; PREDNISONE; THALIDOMIDE; THAPSIGARGIN; UNCLASSIFIED DRUG;

ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER LOCALIZATION; CANCER PAIN; CLINICAL TRIAL; GOLD STANDARD; HUMAN; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; REVIEW;

EID: 33747813799     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2006.06.001     Document Type: Review

References (39)

1. Loberg R.D., Logothetis C.J., Keller E.T., and Pienta K.J. Pathogenesis and treatment of prostate cancer bone metastases: targeting the lethal phenotype. J Clin Oncol 23 (2005) 8232-8241
2. de Wit R. Shifting paradigms in prostate cancer; docetaxel plus low-dose prednisone-finally an effective chemotherapy. Eur J Cancer 41 (2005) 502-507
3. Berry W., and Eisenberger M. Achieving treatment goals for hormone-refractory prostate cancer with chemotherapy. Oncologist 10 (2005) 30-39
4. Tannock I.F., de Wit R., Berry W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (2004) 1502-1512
5. Petrylak D.P., Tangen C.M., Hussain M.H., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351 (2004) 1513-1520
6. Schellhammer P., Cockett A., Boccon-Gibod L., et al. Assessment of endpoints for clinical trials for localized prostate cancer. Urology 49 (1997) 27-38
7. Kelloff G.J., Lieberman R., Steele V.E., et al. Agents, biomarkers, and cohorts for chemopreventive agent development in prostate cancer. Urology 57 (2001) 46-51
8. Parulekar W.R., and Eisenhauer E.A. Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practice. J Natl Cancer Inst 96 (2004) 990-997
9. Braun K., Pipkorn R., and Waldeck W. Development and characterization of drug delivery systems for targeting mammalian cells and tissues: a review. Curr Med Chem 12 (2005) 1841-1858
10. Garber K. Improved Paclitaxel formulation hints at new chemotherapy approach. J Natl Cancer Inst 96 (2004) 90-91
11. Saad F., Clarke N., and Colombel M. Natural history and treatment of bone complications in prostate cancer. Eur Urol 49 (2006) 429-440
12. Hortobagyi G.N. Moving into the future: treatment of bone metastases and beyond. Cancer Treat Rev 31 (2005) 9-18
13. McClung M.R., Lewiecki E.M., Cohen S.B., et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354 (2006) 821-831
14. Arnold J.T., and Isaacs J.T. Mechanisms involved in the progression of androgen-independent prostate cancers: it is not only the cancer cell's fault. Endocr Relat Cancer 9 (2002) 61-73
15. Scher H.I., and Sawyers C.L. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 23 (2005) 8253-8261
16. Denmeade S.R., Jakobsen C.M., Janssen S., et al. Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer. J Natl Cancer Inst 95 (2003) 990-1000
17. Wright Jr. G.L., Grob B.M., Haley C., et al. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 48 (1996) 326-334
18. Henry M.D., Wen S., Silva M.D., Chandra S., Milton M., and Worland P.J. A prostate-specific membrane antigen-targeted monoclonal antibody-chemotherapeutic conjugate designed for the treatment of prostate cancer. Cancer Res 64 (2004) 7995-8001
19. Heinrich P.C., Behrmann I., Haan S., Hermanns H.M., Muller-Newen G., and Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 374 (2003) 1-20
20. Culig Z., Steiner H., Bartsch G., and Hobisch A. Interleukin-6 regulation of prostate cancer cell growth. J Cell Biochem 95 (2005) 497-505
21. Eaton C.L., and Coleman R.E. Pathophysiology of bone metastases from prostate cancer and the role of bisphosphonates in treatment. Cancer Treat Rev 29 (2003) 189-198
22. Smith P.C., and Keller E.T. Anti-interleukin-6 monoclonal antibody induces regression of human prostate cancer xenografts in nude mice. Prostate 48 (2001) 47-53
23. Hibi T., and Yoshizawa S. Infliximab(chimeric monoclonal antibody to tumor necrosis factor alpha). Nippon Rinsho 60 (2002) 480-486
24. Mastroianni A., Minutilli E., Mussi A., et al. Cytokine profiles during infliximab monotherapy in psoriatic arthritis. Br J Dermatol 153 (2005) 531-536
25. Murphy G. Atrasentan for metastatic hormone refractory prostate cancer. Issues Emerg Health Technol (2005) 1-4
26. Jimeno A., and Carducci M. Atrasentan: a novel and rationally designed therapeutic alternative in the management of cancer. Expert Rev Anticancer Ther 5 (2005) 419-427
27. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer 95 (2002) 281-286
28. Eastham J.A. High-risk localised prostate cancer: multimodal treatment strategies combining neoadjuvant hormonal therapy and/or chemotherapy with radical prostatectomy. Expert Opin Emerg Drugs 8 (2003) 291-295
29. D'Amico A.V., Cote K., Loffredo M., Renshaw A.A., and Schultz D. Determinants of prostate cancer specific survival following radiation therapy during the prostate specific antigen era. J Urol 170 (2003) S42-S46 discussion S46-7
30. Freedland S.J., Humphreys E.B., Mangold L.A., et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 294 (2005) 433-439
31. Oh W.K. High-risk localized prostate cancer: integrating chemotherapy. Oncologist 10 (2005) 18-22
32. Bonadonna G., and Valagussa P. Current status of adjuvant chemotherapy for breast cancer. Semin Oncol 14 (1987) 8-22
33. Akduman B., and Crawford E.D. The management of high risk prostate cancer. J Urol 169 (2003) 1993-1998
34. Ryan C.J., and Eisenberger M. Chemotherapy for hormone-refractory prostate cancer: now it's a question of "when?". J Clin Oncol 23 (2005) 8242-8246
35. Oh W.K., and Kantoff P.W. Treatment of locally advanced prostate cancer: is chemotherapy the next step?. J Clin Oncol 17 (1999) 3664-3675
36. Carducci M.A. What is more exciting? The activity of docetaxel in early prostate cancer or the successful collaboration between urologists and medical oncologists to complete a study in early prostate cancer?. J Clin Oncol 23 (2005) 3304-3307
37. NIH: National Institute of Health (NIH). CSP #553 chemotherapy after prostatectomy (CAP) for high risk prostate carcinoma [Online]; 2006. Available from URL: http://www.clinicaltrials.gov.
38. NIH: National Institute of Health (NIH). Hormone therapy and radiation therapy or hormone therapy and radiation therapy followed by docetaxel and prednisone in treating patients with localized prostate cancer [Online]; 2006. Available from URL: http://www.clinicaltrials.gov.
39. NIH: National Institute of Health (NIH). Hormone suppression and radiation therapy for 6 months with/without docetaxel for high risk prostate cancer [Online]; 2006. Available from URL: http://www.clinicaltrials.gov.